Showing results (161-170 of 179) with videos related to
Sort By:
Pageof 18
Lancet (London, England)|June 1, 2020
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort studyNicole M Kuderer, Toni K Choueiri, Dimpy P Shah, et al.Nature Genetics|April 5, 2020
A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancerAlex H Wagner, Brian Walsh, Georgia Mayfield, et al.Lancet Regional Health. Americas|March 24, 2025
Associations of COVID-19 vaccination with risks for post-infectious cardiovascular complications: an international cohort study in cancer patients with SARS-CoV-2 infectionEmily Pei-Ying Lin, Chih-Yuan Hsu, Sanjay Mishra, et al.Journal of Thrombosis and Haemostasis : JTH|July 14, 2021
The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19Ang Li, Nicole M Kuderer, Chih-Yuan Hsu, et al.BMC Cancer|March 23, 2023
Impact of COVID-19 in patients on active melanoma therapy and with history of melanomaDouglas B Johnson, Michael B Atkins, Cassandra Hennessy, et al.Genetics in Medicine : Official Journal of the American College of Medical Genetics|February 1, 2022
Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)Peter Horak, Malachi Griffith, Arpad M Danos, et al.Cancers|September 9, 2022
Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort StudyMichael J Wagner, Cassandra Hennessy, Alicia Beeghly, et al.The Lancet. Oncology|February 17, 2018
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysisJennifer L McQuade, Carrie R Daniel, Kenneth R Hess, et al.JAMA Network Open|January 4, 2022
Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United StatesJessica E Hawley, Tianyi Sun, David D Chism, et al.The New England Journal of Medicine|June 15, 2026
Talquetamab-Daratumumab in Relapsed or Refractory MyelomaRoberto Mina, Meral Beksac, Paula Rodríguez-Otero, et al.Pageof 18